Brief: ImmuneOnco Biopharmaceuticals Shanghai Receives NMPA Approval For Clinical Trial Of IMM01 (Timdarpacept)
12/01/2026 10:32
Jan 12 (Reuters) - ImmuneOnco Biopharmaceuticals Shanghai Inc 1541.HK: APPROVAL BY NMPA CHINA FOR CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) FOR ATHEROSCLEROSIS Further company coverage: 1541.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImmuneOnco Biopharmaceuticals (Shanghai)
See all newsBrief: Immuneonco Biopharmaceuticals (Shanghai) To Subscribe For Wealth Management Product For Hk$87.5 Million
Brief: ImmuneOnCo Biopharmaceuticals (Shanghai) To Repurchase H Shares In Open Market
Brief: Immuneonco Biopharmaceuticals (Shanghai)Subscribes For Hk$212 Million Wealth Management Product
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 Million
Brief: ImmuneOnco Biopharmaceuticals Shanghai Receives Approval From NMPA China For Investigational New Drug Application Of IMM0306S